Product Description
PXL770 is a novel drug candidate that directly activates adenosine monophosphate-activated protein kinase (AMPK); Based on its central metabolic role, we believe that targeting AMPK offers the opportunity to pursue a wide range of indications to treat chronic metabolic diseases, including diseases that affect the liver, such as NASH and rare metabolic disorders (e.g. adrenoleukodystrophy). (Sourced from: https://www.poxelpharma.com/en_us/pipeline/nash)
Mechanisms of Action: AMPK Activator
Novel Mechanism: Yes
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: Fast Track - AdrenoleukodystrophyOrphan Drug - AdrenoleukodystrophyOrphan Drug - Kidney Diseases|Polycystic Kidney, Autosomal Dominant *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Poxel
Company Location:
Company CEO:
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count: 1
Highest Development Phases
Phase 2: Adreno-myeloneuropathy
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| START770 | P2 |
Active, not recruiting |
Adreno-myeloneuropathy |
2022-07-29 |